诺和锐30与诺和灵30R治疗2型糖尿病的临床观察  

Compare the Effect of BIAsp30 and BHI30 in Patients with Type 2 Diabetes Mellitus

作　　者：牛晓红[1] 宋祺[1] 李莉[1] 

机构地区：[1]长治医学院附属和济医院内分泌科,046000

出　　处：《长治医学院学报》2009年第6期424-426,共3页Journal of Changzhi Medical College

摘　　要：目的:观察比较2型糖尿病患者在两个连续阶段使用诺和锐30(预混双时相门冬胰岛素70/30)与诺和灵30R(预混双时相人胰岛素70/30)的治疗效果。方法:52名2型糖尿病患者入选该研究,年龄(58±11.2)岁,糖尿病病程(8±2.1)年,使用诺和灵30R(2±0.4)年,血清空腹c-肽(2.8±0.34)nmol/L。在8周的基线期内进行了一次体格检查,并测定3d的空腹+三餐后2h血糖,随后诺和灵30R改为相似剂量的诺和锐30(P>0.05);在第17周、第25周的阶段,进行两次体格检查,并分别测定3d的空腹+三餐后2h血糖。结果:从诺和灵30R转换为诺和锐30后,HbA1c从第一次体检时的(8.1±1.8)%降至第二次体检时的(7.8±1.6)%(P<0.05);第三次体检时降至(7.4±1.5)%(P<0.01)。空腹血糖有下降趋势,但无统计学差异(P>0.05);平均餐后2h血糖明显下降(P<0.01);而脂蛋白、体重、肝肾功能的生化指标无显著变化;低血糖的发生率相似。结论:使用预混双时相门冬胰岛素70/30在2型糖尿病常规治疗中优于预混双时相人胰岛素70/30。Objective： The aim of this prospective observational open - label controlled study was to compare the effects of BI- Asp30 and BHI30 resulting from their sequential long - lasting routine administration to individuals with type 2 diabetes according to identical algorithms. Methods： Fifty- two individuals with type 2 diabetes （58 ±11.2）（mean ＋/- SE） years old with diabetes＇ duration of （8 ± 2.1 ） years, treated with BHI30 for （2 ± 0.4） years, and a serum C - peptide level of （2.8 ±0. 34） nmol/L were enrolled into the study. Following a checkup performed in the course of the 8 week baseline period, BHI30 was replaced with BI- Asp30 in equivalent boluses, and two checkups in the seventeenth week and twenty - fifth week were performed. Blood glucose at 4time points, glycosylated hemoglobin and hypoglycemia were observed. Results： Following the switch from BHI30 to BIAsp30, hemoglobin Ale （HbAlc） decreased from （8.1 ± 1.8）% at baseline to （7.8±1.6）% （ P 〈 0.05） ,and thereafter to （7.4 ~ 1.5） % （ P 〈 0.01 ）,while the postprandial blood glucose concentration was significandy lower （ P 〈 0.01 ）,and fasting blood glucose concentration was slightly lower（ P 〉 0.05）,and the frequency of hypoglycemia was similar（ P 〉 0.05）. No significant change of lipoprotein, biochemical index of function of liver and kidney, and body mass index（BMI） was found. Conclusion： BIAsp30 is more effective than BHI30 for insulin treatment in individuals with type 2 diabetes.

关 键 词：诺和锐30 诺和灵30R 2型糖尿病 胰岛素 

分 类 号：R587[医药卫生—内分泌]